ArticleInternational journal of clinical pharmacy2026

Cost-effectiveness of first-line pembrolizumab monotherapy in PD-L1-high metastatic non-small cell lung cancer in Australia: evidence from trials and real-world practice.

Srinivas Teppala et al.PubMed ↗Publisher ↗

No numbers read from the abstract.